NCT05849922: A reported trial by Sanofi
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT05849922 |
|---|---|
| Title | A Randomized, Double-blind, Placebo-controlled, Proof-of-concept Study Assessing the Efficacy and Safety of an Anti-TNF-OX40L NANOBODY® Molecule, SAR442970, in Participants With Moderate to Severe Hidradenitis Suppurativa |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | June 6, 2023 |
| Completion date | Aug. 22, 2024 |
| Required reporting date | Aug. 22, 2027, midnight |
| Actual reporting date | Dec. 3, 2025 |
| Date last checked at ClinicalTrials.gov | June 19, 2026 |
| Days late | None |